Evidence-Based Oncology > February 2017
Evidence-Based Oncology – February 2017
February 14, 2017 – Joseph Alvarnas, MD
A note from the editor-in-chief.
February 14, 2017 – Shawn M. Regis, PhD
Patient navigation is immensely helpful in relieving some of the burden placed on cancer patients, and there are some particularly unique aspects of navigation as it pertains to immuno-oncology.
February 14, 2017 – Bruce A. Feinberg, DO; Jennifer Fillman, MBA; Justin Simoncini, MBA, MPH; and Chadi Nabhan, MD, MBA, FACP
An update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
February 15, 2017 – Sumeet Chandra, MD
Community oncologists will be at the forefront of using immunotherapies and will need to be strong advocates for greater information and affordability of therapies.
February 15, 2017 – Surabhi Dangi-Garimella, PhD
Immunotherapy treatments are not without side effects. What do patients and their families need to know so they are more aware?
February 16, 2017 – Michael V. Seiden, MD, PhD; Marcus Neubauer, MD; and Diana Verrilli
The shift to value-based care, concurrent with innovations in immune-based care, will create challenges in oncology. What should be the physician and manufacturer responsibility during these changing times?
February 16, 2017 – Claire Saxton, MBA; Joanne Buzaglo, PhD; Sue Rochman, MA; and Alexandra Zaleta, PhD
Patients, caregivers, and providers need education on immunotherapy treatment, support in patient-provider communications as well as support in mitigating the financial impact of immunotherapy treatment.
February 16, 2017 – Surabhi Dangi-Garimella, PhD
An oncologist provides insight on his experience with using CAR-T therapy in the clinic and his prediction for the future of this revolutionary treatment.
February 13, 2017 – Surabhi Dangi-Garimella, PhD
February 13, 2017 – Produced by Nicole Beagin and Laura Joszt
AJMCtv® interviews let you catch up with experts in healthcare. Topics include challenges with immuno-oncology, including the patient voice in treatment decisions, and why payers should cover genomic testing.